media – Page 612 – DrugDu- Global Leading Pharmaceutical & Medical Device Platform

Tudorza reduces exacerbations and demonstrates cardiovascular safety in COPD patients

AstraZeneca today announced positive top-line results of the Phase IV ASCENT trial for Tudorza Pressair (aclidinium bromide 400 μg, twice-daily), a long-acting muscarinic antagonist (LAMA), in patients with moderate to very severe chronic obstructive pulmonary disease (COPD), with a history of cardiovascular disease and/or significant cardiovascular risk factors.
- Source: Astrazeneca
- 638
- December 8, 2017
AstraZeneca cardiovascular Clinical Trials COPD
FDA Grants Genentech’s Avastin Full Approval for Most Aggressive Form of Brain Cancer

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced that the U.S. Food and Drug Administration (FDA) has granted full approval for Avastin® (bevacizumab) for the treatment of adults with glioblastoma that progressed following prior therapy (referred to as recurrent disease). Avastin was previously granted provisional approval in this setting under the FDA's accelerated approval program.
- Source: Gene
- 573
- December 8, 2017
FDA Genentech New Approvals Roche
Obsidian Therapeutics Announces $49.5 Million Series A Financing to Develop Controllable Cell and Gene Therapy Products

Obsidian Therapeutics, Inc., a biotechnology company dedicated to the development of next-generation cell and gene therapies with pharmacologic operating systems, announced the completion of a $49.5 million Series A financing to further build its technology platform and advance its lead programs toward clinical development.
- Source: Businesswire
- 569
- December 8, 2017
CAR–T Market Views Series
Winter could ‘break the backbone’ of the NHS

Health service experts are warning that the NHS could be “sorely tested” in the coming months as it is already running at near maximum capacity with “severe pressure” on the horizon.
- Source: pharmatimes
- 520
- December 8, 2017
NHS Policy
Personalised epilepsy seizure prediction a possibility with AI

The idea of personalised seizure prediction for epilepsy is closer to becoming a reality thanks to new research published today by the University of Melbourne and IBM Research-Australia.
- Source: medicalxpress
- 663
- December 7, 2017
AI epilepsy Researches
3-D mini brains accelerate research for repairing brain function

Three-dimensional neural circuit "asteroid" composed of neurons (blue) and astrocytes (red and green) generated from human pluripotent stem cells.
- Source: sciencedaily
- 441
- December 7, 2017
human stem cells mini brains
Diphtheria is spreading fast in Cox’s Bazar, Bangladesh

Diphtheria is rapidly spreading among Rohingya refugees in Cox’s Bazar, Bangladesh, WHO warned today.
- Source: reliefweb.int
- 941
- December 7, 2017
Diphtheria WHO
Down’s syndrome research breaks new ground

Down's syndrome, also known as trisomy 21, is one of the most common genetic diseases. Researchers from the University of Geneva (UNIGE) and ETH Zurich (ETHZ), Switzerland, have recently analysed the proteins of individuals with trisomy 21 for the first time: the goal was to improve our understanding of how a supernumerary copy of chromosome 21 could affect human development. Published in the journal Nature Communications, the research shows that trisomy 21, far from only affecting the proteins encoded by the chromosome 21 genes, also impacts on the proteins encoded by the genes located on the other chromosomes.
- Source: Medicalxpress
- 620
- December 7, 2017
Down's syndrome Researches
First Video Game Therapy Heads to FDA As Akili Touts ADHD Study Win

For the first time ever, a mobile video game used to assess and treat a disease is headed for an FDA review.
- Source: xconomy
- 501
- December 7, 2017
ADHD Attention Performance Index Company Insight video game
Cambridge’s Exonics Therapeutics Scores $40M

Exonics Therapeutics closed on a $40 million Series A financing. It was led by The Column Group.
- Source: biospace
- 544
- December 7, 2017
DMD Market Views neuromuscular Series

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.